Products
RECELL® System
Products
RECELL® System
Providing point-of-care, multi-cell regenerative skin restoration with RECELL® System
The RECELL System is approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes.
Multi-use RECELL GO
Processing Device
Single-use
RECELL GO Cartridge
WOUND HEALING
thermal burn wounds | full-thickness skin defects
REPIGMENTATION
vitiligo patients
Providing point-of-care, multi-cell regenerative skin restoration with RECELL® System
Multi-use RECELL GO
Processing Device
Single-use
RECELL GO Cartridge
WOUND HEALING
thermal burn wounds | full-thickness skin defects
REPIGMENTATION
vitiligo patients
Benefits Beyond Closure™
Expedite the healing process with early treatment at a cellular level
RECELL uses a small piece of the patient’s skin to create a multi-phenotype suspension of Spray-On Skin™ Cells.1 The application of different cell types stimulates healing and repigmentation throughout the wound bed.2,3
The power of multi-phenotype Spray-On Skin Cells.
Autologous therapy at point-of-care allows for delivery of the patient’s own living cells:
KERATINOCYTES
regenerate the epidermis4,5
Dermal FIBROBLAST
depost new extraceullular matrix proteins4
TREATING MORE with Less
Caring for your patients means more than closing the wound. With RECELL, you can expedite the healing process with early point-of-care treatment of thermal burn wounds and full-thickness skin defects providing the best possible outcomes for patients. Designed for donor sparing, significantly less donor skin is required with similar healing outcomes versus conventional autografting.
%
Your Title Goes Here
Average less
Donor Skin for
DPT BURNS6
%
Your Title Goes Here
AVERAGE LESS DONOR
SKIN FOR FULL-THICKNESS
BURNS WHEN USED
IN COMBINATION WITH
AUTOGRAFT7
%
Your Title Goes Here
AVERAGE LESS DONOR
SKIN FOR FULL-THICK
NESS SKIN DEFECTS
WHEN USED IN COMBINA
TION WITH AUTOGRAFT8
STEP-BY-STEP Immediate Cellular Delivery
Cost-effective point-of-care regenerative therapy
in a single procedure8,9
Clinical benefits of RECELL can lead to cost savings.9
Reduced donor skin requirements can result in fewer surgical
procedures for definitive closure, decreased length of stay, and
reduced resource use, translating to potential cost savings.9-12
%
Your Title Goes Here
UP TO 50% REDUCTION
IN DEFINITIVE CLOSURE
PROCEDURES9
%
Your Title Goes Here
UP TO 47% REDUCTION
IN LENGTH OF STAY
FOR BURNS <50% TBSA9
%
Your Title Goes Here
UP TO 39% TOTAL
COST SAVINGS9
HOW THE RECELL SYSTEM WORKS
Explore the New FDA-Approved RECELL GO®
Introducing the new FDA-approved RECELL GO System, a breakthrough in regenerative medicine that streamlines the preparation of Spray-On Skin Cells. This next-generation device significantly reduces the training burden on medical staff, improves operating room workflow efficiency, and controls the RECELL Enzyme™ incubation time to ensure optimal cell yield and viability. These advancements simplify the user interface, enabling medical teams to provide consistent, high-quality care in the treatment of partial-thickness and full-thickness wounds.
The proven benefits of RECELL delivered at the touch of a button
Step 1:
Load the RECELL Enzyme, buffer and harvested donor skin into the RECELL GO Cartridge.
Step 2:
Place the Cartridge into the RECELL GO Processing Device and press START.
Step 3:
Aseptically draw up and apply the RECELL Spray-On Skin Cells.
Patients treated with RECELL Spray-On-Skin™ Cells
versus standard of care for small deep partial-thickness
and full-thickness burns experience shorter hospital
stays to help allow a faster return home.9
Patients treated with RECELL Spray-On-Skin™ Cells versus standard of care for small deep partial-thickness and full-thickness burns experience shorter hospital stays to help allow a faster return home.9
Resources that support you and your patients
HCP Resources
REIMBURSEMENT SUPPORT SERVICES
AVITA Medical is committed to providing comprehensive RECELL reimbursement support through the RECELL Access Program. This program delivers the value of a direct, one-stop reimbursement resource for patients, surgeons, and hospital facilities.
Staffed by reimbursement experts, the program offers a range of services, including:
- Pre-authorization services
- Insurance appeals support
- RECELL reimbursement questions
To learn more, contact us at:
Telephone: (833) 674-1688
FAX: (661) 749-9430
Email: [email protected]
1. Wood FM, Giles N, Stevenson A, Rea S, Fear M. Characterisation of the cell suspension harvested from the dermal epidermal junction using a ReCell® kit. Burns. Published online November 12, 2011. doi:10.1016/ j.Burns.2011.03.
2. Navarro FA, Stoner ML, Lee HB, et al. Melanocyte repopulation in full-thickness wounds using a cell spray apparatus. J Burn Care Rehabil 2001;22:41–6.
3. Navarro FA, Stoner ML, Park CS, et al. Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model. J Burn Care Rehabil 2000;21:513–8.
4. Freedberg I, Tomic-Canic M, Komine M, et al. Keratins and the Keratinocyte Activation Cycle J Invest Dermatol 116:633-640, 2001.
5. Hirobe T. Keratinocytes regulate the function of melanocytes. Dermatol Sin. 2014;32(4):200-204.
6. Holmes JH, Molnar JA, Carter JE, et al. A comparative study of the RECELL® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. J Burn Care Res.2018 Aug 17;39(5):694-702.
7. Holmes JH, Molnar JA, Shupp JW, et al. Demonstration of the safety and effectiveness of the RECELL® system combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. Burns.2019;45(4):
8. Instructions for Use. RECELL® Autologous Cell Harvesting Device.
9. Kowal S, Kruger E, Bilir P, et al. Cost effectiveness of the use of autologous cell harvesting device compared to standard of care for treatment of severe burns in the United States. Adv Ther.Published online May 7, 2019. doi: 10.1007/s12325-019-00961-2.
10. Foster K, Bilir P, Kruger E, et al. Cost-effectiveness of RECELL® Autologous Cell Harvesting Device (ACHD) versus STSG for treatment of severe burns in the United States. Presented at the American Burn Association 2018 Annual Meeting, April 2018.
11. Carter JE, Carson JS, Hickerson WL, et al. Length of Stay and Costs with Autologous Skin Cell Suspension Versus Split-Thickness Skin Grafts: Burn Care Data from US Centers [published online ahead of print, 2022 Sep 14]. Adv Ther.2022;10.1007/s12325-022-
12. Carson JS, Carter JE, Hickerson WL, et al. Analysis of real-world length of stay data and costs associated with use of autologous skin cell suspension for the treatment of small burns in U.S. centers [published online ahead of print, 2022 Dec 5]. Burns. 2022; S0305-4179(22)00299-6. doi: 10.1016/j. burns.2022.11.007.
Have questions?
Physicians: stay in touch
Sign Up to
Stay Connected